Macías J, et al. - This work was performed with the goal to compare the effect of switching efavirenz (EFV) to raltegravir (RAL) on hepatic steatosis among HIV-infected patients with nonalcoholic fatty liver disease (NAFLD) receiving EFV plus 2 nucleoside analogues. After 48 weeks, a decrease in the degree of hepatic steatosis was observed among HIV-infected individuals switching EFV to RAL, as measured by CAP, compared with those continuing with EFV. In addition, patients who switched to RAL had a lower prevalence of significant hepatic steatosis after 48 weeks.